New hope for PNH patients when standard treatments fail
NCT ID NCT07154745
Summary
This study is testing a combination of two new drugs, pozelimab and cemdisiran, for people with PNH whose current standard treatment isn't fully controlling the disease. The goal is to see if this new combination can better reduce the destruction of red blood cells and improve symptoms like fatigue. The study will enroll about 35 adults who are already on a C5 inhibitor but still have high levels of a blood marker (LDH) showing their disease is active.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PAROXYSMAL NOCTURNAL HEMOGLOBINURIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
AOU Careggi
RECRUITINGFlorence, Tuscany, 50134, Italy
-
Ewha Womans University Mokdong Hospital
RECRUITINGSeoul, 07985, South Korea
-
Hospital San Pedro de Alcantara
RECRUITINGCáceres, 10003, Spain
-
In-Vivo Sp. z o.o.
RECRUITINGBydgoszcz, Kuyavian-Pomeranian Voivodeship, 85-048, Poland
-
Seoul National University Hospital
RECRUITINGSeoul, 03080, South Korea
Conditions
Explore the condition pages connected to this study.